XELOX+Sintilimab+HBOT
Phase 2Small molecule
XELOX+Sintilimab+HBOT is one of 6 small molecule programs targeting Sintilimab. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Sintilimab
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Lenvima
EisaiPhase 3
Experimental Drug
MMedesis Pharma SA
Phase 3
Sintilimab Plus Chemotherapy
FFudan University
Phase 2
XELOX+Sintilimab+HBOT
WWest China Hospital
Phase 2
Sintilimab Combined With Anlotinib
ZZhejiang Cancer Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XELOX+Sintilimab+HBOT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- WWest China Hospital